Treatment for Late-Onset Obsessive-Compulsive Disorder with Parkinsonism
Despite recognizing for nearly a century the possible association between OCD and parkinsonism, treatment needs of this special group remain relatively unexplored. Common therapeutic strategies for OCD like serotonin reuptake inhibitors (SSRIs) might aggravate motor symptoms by stimulating 5-HT2 receptors and inhibiting dopamine release in the basal ganglia. 28 – 33 On the other hand, L -dopa for parkinsonism is reported to aggravate compulsive and impulsive symptoms. 34 – 36 Patients exhibiting both obsessive and parkinsonian features thus provide a therapeutic challenge for the clinician. A few studies have demonstrated the safety and efficacy of tricyclic antidepressants in depression with parkinsonism but have not clearly commented on the effect on motor features. 37 – 40 OCD with parkinsonism, however, has not been satisfactorily addressed.
We present a naturalistic follow-up study of a group of late-onset OCD patients exhibiting parkinsonian signs who demonstrated a response to clomipramine, which might be considered a viable option for such patients.
METHOD
The patients were seen in the psychiatry clinic of a superspecialty tertiary care hospital in India over a span of 1 year. The hospital serves as the culmination point for many chronic and difficult-to-treat cases. This paper describes 10 patients who were diagnosed with OCD according to ICD-10 criteria and who showed parkinsonian signs (not deemed to be the effect of drugs). Two OCD patients without parkinsonian signs and one who did not undergo investigations were excluded from the study. Patients were rated on the Yale-Brown Obsessive Compulsive Scale, a 10-item scale that rates severity of obsessive-compulsive symptoms, 41 and the Webster Scale for severity of parkinsonian features (bradykinesia, rigidity, gait, arm swing, tremor, and facial expression). 42 We obtained cardiology, prostate, and glaucoma tests and clearance for starting tricyclic antidepressants. Patients were started on a regimen of clomipramine following the principle of starting low and going slow, and the dose was titrated on the basis of clinical improvement and tolerability. We periodically rated the patients on the Visual Analogue Scale, the Yale-Brown Obsessive-Compulsive Scale, and the Webster Scale through December 2006.
RESULTS
The sociodemographic and clinical profile of patients are summarized in Table 1 . Table 2 demonstrates past treatment history. All patients had late age of onset for OCD, and most had demonstrable basal ganglia/frontal subcortical lesions. Table 3 shows patients’ robust and early responses to low doses of clomipramine.
DISCUSSION
This case series is notable as it presents a large series of patients presenting with late-onset obsessive-compulsive disorder exhibiting parkinsonian signs, with demonstrable lesions in the basal ganglia and/or frontal subcortical structures on MRI. All patients consulted a psychiatrist due to dysfunction resulting from OCD, and motor signs were elicited on evaluation. Potential confounding factors were avoided as their obsessive symptoms were not L -dopa induced, nor were motor signs antipsychotic induced (patient 9, with history of antipsychotic treatment, had a 6 month drug-free interval before baseline assessment). The cases support the view that lesions of the basal ganglia could account for OCD as well as parkinsonism. Recognition of behavioral as well as motor features is essential, as such patients present a diagnostic and therapeutic challenge. A diagnosis of late-onset OCD with parkinsonism is often shrouded in therapeutic nihilism as several authors have observed limited response to psychotropic medication 20 and aggravation of motor symptoms with SSRIs. 28 – 33 Our case study gives us reason to be hopeful, as all patients (including past nonresponders to SSRIs) showed an early and robust response to low doses of clomipramine without significant adverse effects. A concomitant decline in the Webster score was an added benefit. Sedative and anxiolytic effects of clomipramine obviated the need for benzodiazepines in all except two cases, avoiding drug interactions and the adverse cognitive effects of benzodiazepines noted in parkinsonism. Although our study is limited by the narrow population sample, it indicates a need for evolution of therapeutic strategies that address both behavioral and motor components of obsessive-compulsive disorder with basal ganglia lesions.
1 . Maia AF, Barbosa ER, Menezes PR: Relationship between obsessive compulsive disorders and diseases affecting primarily the basal ganglia. Rev Hosp Clin Fac Med S Paulo 1999; 54:213–221Google Scholar
2 . Cheyette SR, Cummings J: Encephalitis lethargica: lessons for contemporary neuropsychiatry. J Neuropsychiatry Clin Neurosci 1995; 7:125–134Google Scholar
3 . Schilder P: The organic background of obsessions and compulsions. Am J Psychiatry 1938; 94:1397–1413Google Scholar
4 . Carsen S, Xia C: Editorial. McGill J Med 2006; 9:80–81Google Scholar
5 . Baxter LR, Phelps ME, Mazziotta JC, et al: Local cerebral glucose metabolic rates in obsessive-compulsive disorder: a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987; 44:211–218Google Scholar
6 . Baxter LR, Schwartz JM, Mazziotta JC, et al: Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 1988; 145:1560–1563Google Scholar
7 . Luxenberg JS, Swedo SE, Flament MF: Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative x-ray computed tomography. Am J Psychiatry 1988; 145:1089–1093Google Scholar
8 . Robinson D, Wu H, Munne RA, et al: Reduced caudate nucleus volume in obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52:393–398Google Scholar
9 . Pujol J, Soriano-Mas C, Alonso P, et al: Mapping structural brain alterations in obsessive-compulsive disorder. Arch Gen Psychiatry 2004; 61:720–730Google Scholar
10 . Baxter LR, Schwartz JM, Bergman KS: Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:681–689Google Scholar
11 . Model JG, Mountz JM, Cortis GC: Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive compulsive disorder. J Neuropsychiatry Clin Neurosci 1989; 1:27–36Google Scholar
12 . Graybiel AM, Rauch SL: Toward a neurobiology of obsessive-compulsive disorder. Neuron 2000; 28:343–347Google Scholar
13 . Laplane D, Levasseur M, Pillon B, et al: Obsessive-compulsive and other behavioral changes with bilateral basal ganglia lesions. Brain 1989; 112:699–725Google Scholar
14 . Weilburg JB, Mesulam MM, Weintraub S: Focal striatal abnormalities in a patient with obsessive-compulsive disorder. Arch Neurol 1989; 46:233–235Google Scholar
15 . Croisile B, Tourniaire D, Confavreux C, et al: Bilateral damage to the head of the caudate nuclei. Ann Neurol 1989; 25: 313–314Google Scholar
16 . Ward C: Transient feelings of compulsion caused by hemispheric lesion: 3 cases. J Neurol Neurosurg Psychiatry 1988; 51:266–268Google Scholar
17 . Lopez-Rodriguez F, Gunay I, Glaser N: Obsessive compulsive disorder in a woman with left basal ganglia infarct: a case report. Behavioral Neurology 1997; 10:101–103Google Scholar
18 . Williams AC, Owen C, Heath DA: A compulsive movement disorder with cavitation of the caudate nucleus. J Neurol Neurosurg Psychiatry 1998; 51:447–448Google Scholar
19 . Chacko RC, Corbin MA, Harper RG: Acquired obsessive-compulsive disorder associated with basal ganglia lesions. J Neuropsychiatry Clin Neurosci 2000; 12:269–272Google Scholar
20 . Weiss AP, Jenike MA: Late onset obsessive-compulsive disorder: a case series. J Neuropsychiatry Clin Neurosci 2000; 12:265–268Google Scholar
21 . Stein MB, Heuser IJ, Juncos JL, et al: Anxiety disorders in patients with Parkinson’s disease. Am J Psychiatry 1990; 147:217–220Google Scholar
22 . Lauterbach EC, Duvoisin RC: Anxiety disorders in familial parkinsonism (letter). Am J Psychiatry 1991; 148:274Google Scholar
23 . Richard IH, Schiffer RB, Kurian R: Anxiety and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1996; 8:383–392Google Scholar
24 . Tomer R, Levin BE, Weiner WJ: Obsessive-compulsive symptoms and motor asymmetries in Parkinson’s disease. Neuropsych Neuropsychol Behav Neurol 1993; 6:26–30Google Scholar
25 . Muller N, Putz A, Kathmann N, et al: Characteristics of obsessive-compulsive symptoms in Tourette’s syndrome, obsessive-compulsive disorder and Parkinson’s disease. Psychiatry Res 1997; 70:105–114Google Scholar
26 . Alegret M, Junque C, Vallderiola F: Obsessive-compulsive symptoms in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2001; 70:394–396Google Scholar
27 . Maia AF, Barbosa ER, Menezes PR: Obsessive-compulsive symptoms, obsessive-compulsive disorder and related disorders in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2003; 15:371–374Google Scholar
28 . Chouinard G, Sultan S: A case of Parkinson’s disease exacerbated by fluoxetine. Human Psychopharmacol 1992; 7:63–66Google Scholar
29 . Steur EN: Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43: 211–213Google Scholar
30 . Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G: Parkinsonism exacerbated by paroxetine. Neurology 1994; 44:2406Google Scholar
31 . Richard IH, Kurian R: A survey of antidepressant drug use in Parkinson’s disease. Parkinson Study Group. Neurology 1997; 49:1168–1170Google Scholar
32 . van de Vijver DA, Roos RA, Jansen PA: Start of SSRI and increase in antiparkinsonian drug treatment in patients on L -dopa. Br J Clin Pharmacol 2002; 54:168–170 Google Scholar
33 . Avila A, Cardona X, Maho P, et al: Does nefazodone improve both depression and Parkinson’s disease? A pilot randomized trial. J Clin Psychopharmacology 2003; 23:509–513Google Scholar
34 . Cools R, Barker RA: L -Dopa increases impulsivity in patients with Parkinson’s disease. Neuropsychologia 2003; 41:1431–1441 Google Scholar
35 . Pontone G, Williams JR, Bassett SS, et al: Clinical features associated with impulse control disorders in Parkinson’s disease. Neurology 2006; 67:1258–1261Google Scholar
36 . Voon V, Hassan K, Zurowski M, et al: Prevalence of repetitive and reward seeking behaviors in Parkinson’s disease. Neurology 2006; 67:1254–1257Google Scholar
37 . Laitinen L: Desipramine in treatment of Parkinson’s disease: a placebo controlled study. Acta Neurol Scand 1969; 45:109–113Google Scholar
38 . Andersen J, Aabro E, Gulmann N: Antidepressant treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L -dopa. Acta Neurol Scand 1980; 62:210–219 Google Scholar
39 . Klaassen T, Verhey FR, Sneijders GH: Treatment of depression in Parkinson’s disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 1995; 7:281–286Google Scholar
40 . Vaida FJ, Solinas C: Current approaches to management of depression in Parkinson’s disease. J Clin Neurosci 2005; 12:739–743Google Scholar
41 . Goodman WK, Price LH, Rasmussen SA: The Yale-Brown Obsessive Compulsive scale, part 1: development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006–1011Google Scholar
42 . Webster DD: Critical analysis of the disability in Parkinson’s disease. Mod Treat 1968; 5:257–282Google Scholar